Compare Microsoft (MSFT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs TransMedics Group Inc — how do they compare? Microsoft trades at $535.07 (market cap $3.88T), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Microsoft is far larger — about 1416.1× TransMedics Group Inc's market cap, and Microsoft pays a 0.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and TransMedics Group Inc for 24 Days on average.
| MSFT | TMDX | |
|---|---|---|
Market Cap | $3.88T | $2.74B |
Volume | 19,593,392 | 949,331 |
Sector | Technology | Health |
52-Week High | $542.07 | $150.42 |
52-Week Low | $352.83 | $61.99 |
Typical Hold Time | 142 Days | 24 Days |
Enterprise Value | $3.86T | $3.13B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $522.61, down 1.35% on the day, with strong technical support at $517 and resistance at $530. The company demonstrates robust fundamentals with 2025 revenue of $281.72B and net income of $101.83B, maintaining a 40.31% net margin. Recent earnings beats and bullish analyst consensus support the stock's long-term growth trajectory despite near-term volatility.
Outlook remains positive with 81.7% analyst buy ratings and $571.76 consensus price target, representing 9.4% upside. Key risks include increased capital expenditure concerns and competitive pressures in AI, but Microsoft's strong cloud positioning and consistent earnings growth provide solid foundation for investor confidence.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
